The publication of the Phase III AEGIS-H2H data at the United European Gastroenterology Week, comparing Feraccru/Acccrufer with the leading intravenous (IV) iron (Ferinject), confirmed non-inferiority and showed that Feraccru prevented the recurrence of iron deficiency anaemia (IDA) over 52 weeks, whereas 39% of those on Ferinject required at least one additional intervention. The release of these data now allow Norgine to promote these additional benefits in marketed territories as well as s
23 Oct 2019
Shield Therapeutics - Phase IIIb H2H data presented at conference
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Phase IIIb H2H data presented at conference
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.6m
- Published:
23 Oct 2019 -
Author:
Mark Brewer -
Pages:
6
The publication of the Phase III AEGIS-H2H data at the United European Gastroenterology Week, comparing Feraccru/Acccrufer with the leading intravenous (IV) iron (Ferinject), confirmed non-inferiority and showed that Feraccru prevented the recurrence of iron deficiency anaemia (IDA) over 52 weeks, whereas 39% of those on Ferinject required at least one additional intervention. The release of these data now allow Norgine to promote these additional benefits in marketed territories as well as s